Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026

Same author

Lung transplantation in recipients aged ≥70 years: a single-center experience.

JHLT open·2026

Same author

D-Dimer Reporting and Harmonization: Analysis of College of American Pathologists D-Dimer Proficiency Testing Program.

Seminars in thrombosis and hemostasis·2026

Same author

Viscoelastic Testing to Guide Anticoagulation During Extracorporeal Membrane Oxygenation in Lung Transplantation.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026

Same author

Bilateral lung herniation with parenchymal infarction following clamshell thoracotomy for lobar lung transplantation: a case report.

Journal of cardiothoracic surgery·2025

Same author

Lobar lung transplantation, followed by partial sternal resection and bronchial stenosis, in a patient with scoliosis.

Journal of cardiothoracic surgery·2025

Same journal

Waitlist mortality and recovery among pediatric heart transplant candidates in Germany: A nationwide registry analysis.

JHLT open·2026

Same journal

Future prospects of pediatric lung transplantation.

JHLT open·2026

Same journal

Epidemiology of medical emergency team calls in patients undergoing lung transplantation.

JHLT open·2026

Same journal

Drug-coated balloon treatment of in-stent restenosis in complex severe cardiac allograft vasculopathy.

JHLT open·2026

Same journal

Heart-lung transplantation in the United Kingdom: Trends and outcomes over 4 decades.

JHLT open·2026

Same journal

Adoption and challenges of the 2018 International Society for Heart and Lung Transplantation consensus statement on adult and pediatric airway complications grading system in lung transplantation: A multicenter survey.

JHLT open·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 1, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

Anticoagulation Management During ECMO: Narrative Review.

Jaromir Vajter¹, Oksana Volod²

¹Department of Anaesthesiology, Resuscitation, and Intensive Care Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic.

|March 27, 2025

Summary

This summary is machine-generated.

Managing anticoagulation during extracorporeal membrane oxygenation (ECMO) is crucial for preventing clots and bleeding. Current practices involve unfractionated heparin, with emerging tools like viscoelastic assays offering improved monitoring for better patient outcomes.

Keywords:

Anticoagulation Argatroban Bivalirudin ECMO LMWH UFH

More Related Videos

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Published on: October 24, 2018

Related Experiment Videos

Last Updated: Jan 1, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Published on: October 24, 2018

Area of Science:

Cardiology
Hematology
Critical Care Medicine

Background:

Extracorporeal membrane oxygenation (ECMO) is a life-saving therapy for severe cardiorespiratory failure.
Effective anticoagulation is essential to prevent life-threatening thromboembolic events during ECMO.
Managing anticoagulation in ECMO patients presents unique challenges due to coagulopathies and bleeding risks.

Purpose of the Study:

To review current anticoagulation strategies, agents, and monitoring techniques used in ECMO.
To discuss the challenges and emerging insights in ECMO anticoagulation management.
To highlight the importance of individualized approaches and advanced monitoring for optimizing ECMO therapy.

Main Methods:

Review of current literature on anticoagulation practices in ECMO.
Analysis of commonly used anticoagulant agents, including unfractionated heparin, LMWH, and direct thrombin inhibitors.
Evaluation of monitoring methods such as aPTT, ACT, anti-Xa assays, and viscoelastic assays (VEA).

Main Results:

Unfractionated heparin (UFH) is the standard, monitored by aPTT or ACT, with increasing use of anti-Xa and VEA for improved accuracy.
Antithrombin supplementation is recommended when levels drop below 50%-70% to enhance heparin efficacy.
Direct thrombin inhibitors like bivalirudin are alternatives for heparin-induced thrombocytopenia, despite cost and availability issues.

Conclusions:

Anticoagulation management in ECMO is complex, requiring a balance between thrombosis and bleeding risks.
Personalized protocols and point-of-care VEA are emerging as key tools for effective ECMO anticoagulation.
Standardized protocols and ongoing research are vital for optimizing anticoagulation and improving outcomes in high-risk ECMO patients.